Takeda Phamaceutical Co., along with its French subsidiary, Laboratories Takeda, has agreed to withdraw Actos® (pioglitazone) and Competact (pioglitazone and metformin) because of concerns about an increased risk of bladder cancer with the drug.
The two medications are used to treat type II mellitus diabetes which is a form of non-insulin-dependent diabetes. In the U.S., the drug is sold under the name Actos®. Beginning in June of this year, the U.S. Food and Drug Administration added extra warning labels to products containing pioglitazone.
It appears that France is jumping ahead of the United States by making changes to their drug regulations including ensuring that medications sold in France are safe and also improving patient education and information regarding the risks of medication.
The decision to remove Actos® from the French market came after a study in May by Italian researchers who found a connection between Actos® and bladder cancer.
Some bladder cancer patients in the United States may file lawsuits against Takeda Pharmaceutical for failing to adequately test the drug or warn patients about a bladder cancer risk.
This information is provided by Washington Injury Attorney blog, a service of The Farber Law Group. We are a personal injury law firm with more than 40 years experience representing people who have become ill due to dangerous drugs, including Actos® and drugs containing Pioglitazone.
Contact The Farber Law Group at 1-800-244-9087 or email@example.com to schedule a free and confidential case evaluation. We have offices in Seattle and Bellevue to assist you.